New relationships, risks, and business structures are redefining the marketplace. Learn what’s working, and what isn’t, in the race toward value.
Drug companies must join providers, payers, and patients in seeing themselves as stakeholders.
By now, it’s almost old news: big data will transform medicine. It’s essential to remember, however, that data by themselves are useless.
Using patient stratification and more primary care visits, Chicago-based Oak Street Health aims to reduce hospitalizations.
You know what you like in a mobile phone and can compare different models’ quality. How can patients and providers do that in health care?
What payers would like to see when it comes to engagement in value-based reimbursement and building healthier outcomes.
A payer describes the barriers in moving toward value-based drug pricing.
What happens if all drugs are tremendous and are paid their value-based price?
The changes needed in health care are happening way too slowly. Health care stakeholders must must insist on value in what they pay.
Early evidence suggests that value-based payment and care delivery can transform our health care system, but providers must increase the momentum for this positive change.
As health care reform struggles to gain traction legislatively, health care professionals report that payment reforms continue to move forward at a moderate pace, and indeed are essential to achieving the Triple Aim.
David Cutler asks Patrick Conway what worked and what didn’t at CMS, advice he’d give to the Trump administration, and his predictions on Medicare and Medicaid.
Fee-for-service compensation is unsustainable, but what is the solution? Arkansas Blue Cross and Blue Shield’s proactive new payment model reduces payment for low-value care and uses the savings to reward high-value care.
A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.